Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan hydrochloride + albumin bound paclitaxel
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Liposomal irinotecan hydrochloride + albumin bound paclitaxel is an investigational combination regimen consisting of a liposomal formulation of irinotecan hydrochloride (a topoisomerase I inhibitor designed for improved tumor delivery and reduced toxicity compared to conventional irinotecan) and albumin bound paclitaxel (nab-paclitaxel, a microtubule inhibitor complexed with albumin for enhanced tumor targeting). This combination is being studied primarily for potential synergistic efficacy in advanced solid tumors, including gastric cancer and possibly pancreatic cancer. Liposomal irinotecan works by inhibiting DNA replication through topoisomerase I inhibition, thereby inducing apoptosis in rapidly dividing cancer cells. Albumin bound paclitaxel stabilizes microtubules, preventing cell division and leading to apoptosis. The combination aims to leverage the distinct mechanisms for improved anti-tumor activity compared to either agent alone or standard chemotherapy regimens[2].
- Other names
- Irinotecan Hydrochloride Liposome Injection + Paclitaxel For Injection (Albumin Bound)Liposomal Irinotecan Combined With Albumin-bound PaclitaxelLiposomal Irinotecan + Nab-paclitaxel
02
Targets
TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on liposomal irinotecan hydrochloride + albumin bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan hydrochloride + albumin bound paclitaxel.